Kymera Therapeutics (KYMR) Interest Expenses (2019 - 2026)
Kymera Therapeutics (KYMR) reported Interest Expenses of $61000.0 for Q1 2026, down 15.28% year-over-year from $72000.0 in Q1 2025, and down 32.22% quarter-over-quarter from $90000.0 in Q4 2025.
Kymera Therapeutics (KYMR) Interest Expenses (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of Interest Expenses data on file, last reported at $61000.0 in Q1 2026.
- Interest Expenses for Q1 2026 came in at $61000.0, down 15.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $357000.0 (up 41.67% YoY), and the FY2025 annual result was $370000.0, up 48.59% from the prior year.
- Interest Expenses eased to $61000.0 in Q1 2026 per KYMR's latest filing, from $90000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $108000.0 in Q2 2025 and troughed at $36000.0 in Q3 2022.
- A 5-year average of $61823.5 and a median of $59000.0 in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses tumbled 48.57% in 2022, then jumped 77.05% in 2025.
- A 5-year view of Interest Expenses shows it stood at $59000.0 in 2022, then retreated by 11.86% to $52000.0 in 2023, then grew by 13.46% to $59000.0 in 2024, then surged by 52.54% to $90000.0 in 2025, then plunged by 32.22% to $61000.0 in 2026.
- Business Quant data shows KYMR's Interest Expenses at $61000.0 in Q1 2026, $90000.0 in Q4 2025, and $98000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -332,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 61,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -5.58 Mn |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | 61,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61,000.00 |
| Mar 31, 2026 | 61,000.00 |
| Dec 31, 2025 | 90,000.00 |
| Dec 31, 2025 | 90,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Jun 30, 2025 | 108,000.00 |
| Jun 30, 2025 | 108,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Dec 31, 2024 | 59,000.00 |
| Dec 31, 2024 | 59,000.00 |
| Sep 30, 2024 | 60,000.00 |
| Sep 30, 2024 | 60,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Mar 31, 2024 | 69,000.00 |
| Mar 31, 2024 | 69,000.00 |
| Dec 31, 2023 | 52,000.00 |
| Dec 31, 2023 | 52,000.00 |